Ivacaftor

Ivacaftor is a CFTR potentiator that enhances chloride transport in cystic fibrosis patients with gating mutations. Benefits include improved lung function and reduced exacerbations. Side effects include headache, elevated liver enzymes, rash, and abdominal pain. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

Ivacaftor demonstrates a multiaxis biochemical interference profile spanning catalyticdomain perturbation, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential modulation, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular architecture supports docking to catalytic residues, allosteric control nodes, transmembrane helices, nucleotidebinding sites, redoxbuffer matrices and polymeric scaffold proteins. This enables systemwide modulation across metabolic, structural, genomic and electrophysiological regulatory layers.

Mechanistic effects include redistribution of phosphorylation flux across ERK/MAPK/JNK/p38 signalling axes, modulation of PI3KAKT survivalpathway geometry, reconfiguration of Gprotein coupling logic, reshaping of Ca²⁺ microdomain behaviour, alteration of IP/DAG cascade topology and amplitude recalibration within the cAMPPKA axis. Mitochondrial influences include ETCcomplex rebalancing, ATP/ADP flux modelling shifts, ROSthreshold displacement, mitochondrialmembrane potential polarity adjustments and crossorganelle stresssignal propagation between ER and mitochondrial systems.

Advanced

  • Kinomelevel catalyticcascade interference mapping
  • Highprecision ligand docking & conformationaltransition simulations
  • UPR/ERstress, mitophagy & autophagicflux network modelling
  • Multiomics integration (RNAseq, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal mechanics, forcedistribution profiling & polymer turnover
  • Cellfate modelling across apoptosis, necroptosis, ferroptosis & parthanatos
  • SAR/QSAR optimisation with machinelearningbased compound performance modelling

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation & antioxidantbuffer collapse
  • Mitochondrial fragmentation or ETC suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionflux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity failure
  • Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
  • Induction of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert laboratory research only not intended for biological use.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C24H28N2O5

Molecular Weight

392.5 g/mol

CAS Number

873054-44-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

low (<0.05 µg/mL)

Purity

Purity information is available upon request (COA).

Synonym

Ivacaftor; 873054-44-5; VX-770; Kalydeco; N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

IUPAC/Chemical Name

N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide

InChl Key

PURKAOJPTOLRMP-UHFFFAOYSA-N

InChl Code

InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)

References

https://pubchem.ncbi.nlm.nih.gov/compound/16220172;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download